目錄:杭州斯達(dá)特生物科技有限公司>>抗體/抗原>>Biosimilar抗體>> S0B0557Anti-VEGF Monoclonal Antibody(Bevacizumab)
參考價(jià) | ¥ 1700 |
參考價(jià) | ¥ 1700 |
更新時(shí)間:2025-06-12 08:53:04瀏覽次數(shù):23評(píng)價(jià)
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息,謝謝!
Bevacizumab works by blocking a protein called VEGF, which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)